Highlights
- CannPal's lead candidate, CPAT-01, met its primary endpoint in a Phase 2C study in aged beagles with osteoarthritis.
- Argent keeps the intellectual property and the right to manufacture CannEpil at cost plus a Margin of up to 20%.
- The September quarter report, released on 23 October 2026, set out a refocus on immune modulation and inflammatory disease.
- Cash at 30 September 2026 was about AUD 11,000, down from AUD 141,000 at 30 June.
Argent BioPharma (ASX:RGT) has reshaped itself in 2026 by licensing out its most advanced product, the CannEpil epilepsy treatment, in a deal that cleared its main secured Debt rather than delivering cash. The company now relies on future royalties, Manufacturing margins and a convertible funding Facility while it pivots towards immune modulation and inflammatory disease.
What Argent does
Argent is an ASX-listed drug developer working with cannabinoid-based and other medicines. Its portfolio has included CannEpil, a standardised 20:1 cannabidiol to THC oral solution for drug-resistant epilepsy, and CimetrA, an anti-inflammatory candidate. It is not a commercial-scale pharmaceutical company: customer receipts in the September 2026 quarter were about AUD 10,000, according to its quarterly report.
That is a veterinary trial result, not a regulatory approval.
The CannEpil licence
The licensee, now named Endovia Health Sciences, paid a USD 5.5 million upfront fee by forgiving convertible notes held by Mercer Street Global Opportunity Fund. Argent said no new shares were issued for that cancellation, which removed its main secured liability.
It is entitled to a 15% Royalty on human therapeutic sales and, according to its September quarter report, 10% on veterinary applications. The licensee is responsible for US clinical development and an FDA application, with obligations to use commercially reasonable efforts to start a Phase I trial within 24 months. Royalties depend on products reaching market, which has not happened in the US.
New programmes
Priorities include CimetrA, a newly licensed antiviral portfolio (Tollovir, Tollovid and NutraVir) from NLC under an exclusive worldwide licence excluding China, and research into chronic inflammation, with RGT-CA91980 named as the lead internal programme. The company also said the FDA's veterinary centre opened an investigational new animal drug file on 26 August 2026 for a programme initially targeting cancer-related pain in dogs.
Cash and funding
The company drew AUD 600,000 during the quarter from its AUD 11 million convertible securities facility and reported about AUD 7.4 million of unused facilities, giving an estimated 10.1 quarters of funding. After the quarter it disclosed Unsecured Loan facilities of USD 500,000 for working capital.
That runway depends on continued access to the convertible facility, and conversions typically issue shares at a discount, so dilution is an ongoing risk. Other risks include reliance on a licensee to fund CannEpil trials, the early stage of the new pipeline and the low level of current revenue.
Share Trading on 16 November
That compares with a price of AUD 0.034 when the September quarter report was released on 23 October.
_11_16_2026_07_52_44_870464.jpg)




_11_16_2026_07_55_02_604226.jpg)
Please wait processing your request...